{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:30:43Z","timestamp":1761294643150},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"DOI":"10.7759\/cureus.44115","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:42:45Z","timestamp":1692978165000},"source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Moderate Hypophosphatemia on the Clinical Management of Primary Hyperparathyroidism"],"prefix":"10.7759","author":[{"given":"Elif","family":"G\u00fcne\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196605262742105","article-title":"The study of hyperparathyroidism at the Massachusetts General Hospital","volume":"274","author":"Cope O","year":"1966","unstructured":"Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966, 274:1174-82. 10.1056\/NEJM196605262742105","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser WD","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism. Lancet. 2009, 374:145-58. 10.1016\/S0140-6736(09)60507-9","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan AA","year":"2017","unstructured":"Khan AA, Hanley DA, Rizzoli R, et al.. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017, 28:1-19. 10.1007\/s00198-016-3716-2","journal-title":"Osteoporos Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian JP","year":"2014","unstructured":"Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014, 99:3561-9. 10.1210\/jc.2014-1413","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.04.088","article-title":"End-organ effects of primary hyperparathyroidism: a population-based study","volume":"165","author":"Assadipour Y","year":"2019","unstructured":"Assadipour Y, Zhou H, Kuo EJ, Haigh PI, Adams AL, Yeh MW. End-organ effects of primary hyperparathyroidism: a population-based study. Surgery. 2019, 165:99-104. 10.1016\/j.surg.2018.04.088","journal-title":"Surgery"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg SJ","year":"1999","unstructured":"Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999, 341:1249-55. 10.1056\/NEJM199910213411701","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02680.x","article-title":"Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function","volume":"66","author":"Moosgaard B","year":"2007","unstructured":"Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf). 2007, 66:35-42. 10.1111\/j.1365-2265.2006.02680.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab768","article-title":"Is moderate hypophosphatemia a new indication for surgery in asymptomatic primary hyperparathyroidism?","volume":"107","author":"Clarke BL","year":"2022","unstructured":"Clarke BL. Is moderate hypophosphatemia a new indication for surgery in asymptomatic primary hyperparathyroidism?. J Clin Endocrinol Metab. 2022, 107:e1756-7. 10.1210\/clinem\/dgab768","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab676","article-title":"Serum phosphate: a neglected test in the clinical management of primary hyperparathyroidism","volume":"107","author":"Castellano E","year":"2022","unstructured":"Castellano E, Attanasio R, Boriano A, Pellegrino M, Borretta G. Serum phosphate: a neglected test in the clinical management of primary hyperparathyroidism. J Clin Endocrinol Metab. 2022, 107:e612-8. 10.1210\/clinem\/dgab676","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02064-w","article-title":"The importance of hypophosphatemia in the clinical management of primary hyperparathyroidism","volume":"46","author":"D\u00fc\u011fer H","year":"2023","unstructured":"D\u00fc\u011fer H, Bostan H, G\u00fcl \u00dc, et al.. The importance of hypophosphatemia in the clinical management of primary hyperparathyroidism. J Endocrinol Invest. 2023, 46:1935-40. 10.1007\/s40618-023-02064-w","journal-title":"J Endocrinol Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1772","article-title":"Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency","volume":"90","author":"Grey A","year":"2005","unstructured":"Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005, 90:2122-6. 10.1210\/jc.2004-1772","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/cc9215","article-title":"Treatment of hypophosphatemia in the intensive care unit: a review","volume":"14","author":"Geerse DA","year":"2010","unstructured":"Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010, 14:R147. 10.1186\/cc9215","journal-title":"Crit Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris ES","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, et al.. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014, 25:1439-43. 10.1007\/s00198-014-2655-z","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10019","article-title":"Serum calcium to phosphorous (Ca\/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism","volume":"2","author":"Madeo B","year":"2018","unstructured":"Madeo B, Kara E, Cioni K, et al.. Serum calcium to phosphorous (Ca\/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus. 2018, 2:109-17. 10.1002\/jbm4.10019","journal-title":"JBMR Plus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1606","article-title":"Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak","volume":"91","author":"Rendina D","year":"2006","unstructured":"Rendina D, Mossetti G, De Filippo G, Cioffi M, Strazzullo P. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab. 2006, 91:959-63. 10.1210\/jc.2005-1606","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel EA","year":"2012","unstructured":"Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012, 97:696-706. 10.1210\/jc.2011-1319","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","article-title":"Williams Textbook of Endocrinology, 14th Edition","author":"Bringhurst FR","year":"2019","unstructured":"Bringhurst FR, Demay MB, Kronenberg HM.  Williams Textbook of Endocrinology, 14th Edition. Elsevier, Philadelphia, PA; 2019."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh J","year":"2006","unstructured":"Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006, 2:136-48. 10.1038\/ncpneph0124","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12062","article-title":"Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism","volume":"78","author":"Jayasena CN","year":"2013","unstructured":"Jayasena CN, Modi M, Palazzo F, De Silva A, Donaldson M, Meeran K, Dhillo WS. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2013, 78:838-43. 10.1111\/cen.12062","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0931-8","article-title":"Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism","volume":"55","author":"Viccica G","year":"2017","unstructured":"Viccica G, Cetani F, Vignali E, Miccoli M, Marcocci C. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine. 2017, 55:256-65. 10.1007\/s12020-016-0931-8","journal-title":"Endocrine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.75.6.1464657","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees SA","year":"1992","unstructured":"Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab. 1992, 75:1514-18. 10.1210\/jcem.75.6.1464657","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-018-2184-2","article-title":"Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy","volume":"471","author":"Bergwitz C","year":"2019","unstructured":"Bergwitz C, Miyamoto KI. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch. 2019, 471:149-63. 10.1007\/s00424-018-2184-2","journal-title":"Pflugers Arch"},{"key":"ref23","article-title":"Kidney stones: a global picture of prevalence, incidence, and associated risk factors","volume":"12","author":"Romero V","year":"2010","unstructured":"Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010, 12:e86-96.","journal-title":"Rev Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01080","article-title":"Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal status","volume":"102","author":"Castellano E","year":"2017","unstructured":"Castellano E, Attanasio R, Boriano A, Pellegrino M, Garino F, Gianotti L, Borretta G. Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal status. J Clin Endocrinol Metab. 2017, 102:4148-52. 10.1210\/jc.2017-01080","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy170","article-title":"Distinct phenotype of kidney stone formers with renal phosphate leak","volume":"34","author":"Dhayat NA","year":"2019","unstructured":"Dhayat NA, L\u00fcthi D, Schneider L, Mattmann C, Vogt B, Fuster DG. Distinct phenotype of kidney stone formers with renal phosphate leak. Nephrol Dial Transplant. 2019, 34:129-37. 10.1093\/ndt\/gfy170","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-20-0217","article-title":"Isolated hypophosphataemia as an early marker of primary hyperparathyroidism","volume":"2021","author":"Alexander J","year":"2021","unstructured":"Alexander J, Nagi D. Isolated hypophosphataemia as an early marker of primary hyperparathyroidism. Endocrinol Diabetes Metab Case Rep. 2021, 2021:3-7. 10.1530\/EDM-20-0217","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1106636","article-title":"Clinical practice. Primary hyperparathyroidism","volume":"365","author":"Marcocci C","year":"2011","unstructured":"Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med. 2011, 365:2389-97. 10.1056\/NEJMcp1106636","journal-title":"N Engl J Med"},{"key":"ref28","article-title":"The Kidney Physiology and Pathophysiology, 4th Edition","author":"Knochel JP","year":"2008","unstructured":"Knochel JP. The Kidney Physiology and Pathophysiology, 4th Edition. Lippincott, Williams and Wilkins, Philadelphia, PA; 2008."},{"key":"ref29","article-title":"Hypophosphatemia and neurological changes secondary to oral caloric intake: a variant of hyperalimentation syndrome","volume":"73","author":"Silvis SE","year":"1980","unstructured":"Silvis SE, DiBartolomeo AG, Aaker HM. Hypophosphatemia and neurological changes secondary to oral caloric intake: a variant of hyperalimentation syndrome. Am J Gastroenterol. 1980, 73:215-22.","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/181373-the-impact-of-moderate-hypophosphatemia-on-the-clinical-management-of-primary-hyperparathyroidism","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:38Z","timestamp":1707508598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/181373-the-impact-of-moderate-hypophosphatemia-on-the-clinical-management-of-primary-hyperparathyroidism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.44115","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}